Quetiapine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Quetiapine

Examples of brand names: Seroquel [DE]

ATC code: N05AH04

Main use (for orientation): Schizophrenia; bipolar disorder

Documented research summary

A retrospective series provides signals with THC-rich products. The full text contradicts itself on the number of quetiapine cases; do not infer incidence or established CYP causality.

Uncertainties and limitations

Suspected cases involving other medicines; theoretical CYP3A4 explanation not measured. No reliable quantitative CBD–quetiapine exposure change.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Direct pair finding

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Pair-specific evidence, distinguished in the individual findings

Mechanism / drug context: Case signals and pharmacodynamic research; CYP explanations not measured.

Type of supporting material: See the separate original findings

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Quetiapine fumarate, oral prolonged-release tablets; active parent substance and active norquetiapine, not solely a prodrug.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0120]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: QUETIAPINE EXTENDED RELEASE (QUETIAPINE) TABLET, FILM COATED, EXTENDED RELEASE [REMEDYREPACK INC.] [CA_L_D0120]

Source role [CA_P_39502532]: Pair finding

Statement supported: Myocarditis, renal failure and bradycardia/sialorrhoea reported.

Source: Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs. [CA_P_39502532]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THC-rich cannabis products – clinical signals

Finding ID: V6_D0120_1

Type of result: Finding within the documented study context

Observation: Myocarditis, renal failure and bradycardia/sialorrhoea reported.

Mechanism: Mechanism proposed only

Study type: Retrospective case series

Context studied: Chrobak et al. 2024.

Clinical interpretation: Safety signal.

Limitations and uncertainties: Text reports two cases, table three; co-medication, no proven CYP causality.

Original sources for this finding: Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs. [CA_P_39502532]

References and access status

[CA_L_D0120] QUETIAPINE EXTENDED RELEASE (QUETIAPINE) TABLET, FILM COATED, EXTENDED RELEASE [REMEDYREPACK INC.]

Original source / bibliographic reference

Authors: REMEDYREPACK INC.

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_39502532] Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs.

Original source / bibliographic reference

Authors: Chrobak AA, Woroń J, Siwek M.

Year: 2024

Source type: research-article; Journal Article

DOI: 10.3389/fphar.2024.1500312

PMID: 39502532

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CA_P_38950483] Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol.

Original source / bibliographic reference

Authors: Jieu B, Sykorova EB, Rohleder C, Marcolini E, Hoffmann AE, Koethe D, Leweke FM, Couttas TA.

Year: 2024

Source type: Research Support, Non-U.S. Gov't; Clinical Trial, Phase I; Randomized Controlled Trial; Journal Article

DOI: 10.1016/j.psychres.2024.116005

PMID: 38950483

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_22741619] A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.

Original source / bibliographic reference

Authors: Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M.

Year: 2013

Source type: research-article; Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural

DOI: 10.1111/j.1369-1600.2012.00461.x

PMID: 22741619

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility